Premium
Using neural stem cells as an anti‐cancer drug delivery vehicle for treating human breast cancer
Author(s) -
Reuter Ashley,
Davis Kelsey,
Rachakatla Raja Shekar
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.914.1
Subject(s) - breast cancer , cancer cell , in vitro , in vivo , neural stem cell , drug delivery , cancer research , cancer , stem cell , cancer stem cell , medicine , chemistry , biology , microbiology and biotechnology , biochemistry , organic chemistry
The broad, long‐term objective of this lab was to use C 17.2 murine neural stem cells (NSC) as a targeted, drug delivery vehicle to treat tumors. Our goal was to determine if NSC can be used as a drug delivery vehicle to administer interferon beta (IFN‐β) directly to MDA 231 human breast cancer and to look at the therapeutic ability of NSC transduced with IFN‐β (NSC‐IFN‐β) on MDA 231 cells. We addressed two specific aims. Specific aim 1 determined if NSC migrate towards MDA 231 cells in vitro . A transwell plate was seeded with selected concentrations of MDA 231 cells in the lower chambers and NSC in the upper chambers. After 24 hours, the migrated NSC were counted using confocal microscopy. Results There was a significant increase (P<0.001) of NSC migration towards 10,000 and 100,000 MDA 231 cells compared to control. Specific aim 2 determined if NSC‐IFN‐β migrate towards and kill MDA 231 cancer cells in vitro . A transwell plate was seeded with MDA 231 cells in the lower chambers and NSC (control) or NSC‐IFN‐β in the upper chambers. After 48 hours, the live and dead cells were counted. Results The number of live cells significantly decreased (P<0.001) when using NSC‐IFN‐β compared to control. Conclusion NSC and NSC‐IFN‐β migrate towards MDA 231 human breast cancer and NSC‐IFN‐β significantly reduced the number of cancer cells. Future studies include testing NSC‐IFN‐β efficacy on human breast cancer in vivo . Grant Funding Source : A. T. Still University Graduate Program